Previous Study: BCIRG 102
Next Study: CIRG/TORI 010
Studies & Results
BCIRG 103
A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters
View FDA Study
Presentations
San Antonio Breast Cancer Symposium, 2006
Finn R
Results of BCIRG 103: A presurgical study to evaluate molecular alterations that occur in human breast cancer tissue after short-term exposure to gefitinib.
San Antonio Breast Cancer Symposium, 2006
Finn RS, Dering J, Ginther C, et al
Expression of EGFR ligands betacellulin and tenascin C are associated with molecular response following gefitinib treatment in women with primary breast cancer.
ASCO Annual Meeting, 2006
Finn RS, Dering J, Ginther C, et al
ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
San Antonio Breast Cancer Symposium, 2006
Finn R
Results of BCIRG 103: A presurgical study to evaluate molecular alterations that occur in human breast cancer tissue after short-term exposure to gefitinib.
San Antonio Breast Cancer Symposium, 2006
Finn RS, Dering J, Ginther C, et al
Expression of EGFR ligands betacellulin and tenascin C are associated with molecular response following gefitinib treatment in women with primary breast cancer.
ASCO Annual Meeting, 2006
Finn RS, Dering J, Ginther C, et al
ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org